Androgen receptor, in prostate cancer

C24. Culig, Z., Hobisch, A., Hittmair, A., Peterziel, H., Radmayr, C., et al., Hyperactive androgen receptor in prostate cancer What does it mean for new therapy concepts Histol. Histopathol. 12,781-786(1997). 

Heinlein CA, Chang CS. Androgen receptor in prostate cancer. Endocr Rev 2004 25 276-308. 

Baek, S.H., Ohgi, K.A., Nelson, C.A., Welshie, D., Chen, C., Sawyers, C.L., Rose, D.W. and Rosenfeld, M.G. (2006) Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 103, 3100-3105. 

Hawkins EF, Lieskovsky G and Markiand FS Jr (1981) Molybdate and the measurement of androgen receptors in prostate cancer. J Clin Endocrinol Metab 53 456-458. 

Sintokamides A-E are polychlorinated dipeptides isolated from an Indonesian sponge of the genus Dysidea collected at Palau Sintok. Sintokamide A inhibit N-termi-nus transactivation of the androgen receptor in prostate cancer cells, and could be a new drug lead to treat prostate cancer (Sadar et al, 2008). 

Sadar, M.D., Williams, D.E., Mawji, N.R., Patrick, B.O., Wikanta, T., Chasanah, E., Irianto, H.E., Van Soest, R., and Andersen, R.J. (2008) Sintokamides A-E, chlorinated peptides from the sponge Dyadea sp. that inhibit transactivayion of the N-terminus of the androgen receptor in prostate cancer cells. Org. Lett., 10, 4947-4950. 

Lin, D. L., M. C. Whitney, Z. Yao, and E. T. Keller. 2001. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 7(6) 1773—81. 

Synthesis inhibitor—used in androgen receptor-positive prostate cancer. 

Culig Z. Role of the androgen receptor axis in prostate cancer. Urology 2003 62(5 suppl 1) 21—26. 

Xing, N, Y Chen, SH Mitchell, and CYF Young. 2001. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22(3) 409 414. 

Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN (2003) Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22 2466-2477... 

Barrack ER. Androgen receptor mutations in prostate cancer. Mt Sinai J Med 1996 63(5-6) 403-412. 

D12. De Vere White, R., Meyers, F., Chi, S. G., Chamberlain, S., Siders, D., et al., Human androgen receptor expression in prostate cancer following androgen ablation. Eur. Urol. 31, 1-6... 

E6. Emtage, L. A., Dunn, P. J., and Rowse, A. D., Androgen and oestrogen receptor status in benign and neoplastic prostate disease. Study of prevalence and influence on time to progression and survival in prostate cancer treated by hormone manipulation. Br. J. Urol. 63, 627—633 (1989). 

H5. Hardy, D. O., Scher, H. I., Bogenreider, T., Sabbatini, P., Zhang, Z. F., etal., Androgen receptor CAG repeat lenghts in prostate cancer Correlation with age of onset. J. Clin Endocrinol. Metab. 81, 440CM405 (1996). 

K13. Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., et al, Androgen receptor gene amplification a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57, 314-319 (1997). 

K14. Kokontis, J., Takakura, K., Hay, N., and Liao, S., Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 54, 1566-1573 (1994). 

P18. Prins, G. S., Sklarew, R. J., and Perschuck, L. P., Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J. Urol. 159, 641-649 (1998). 

Seghal, I., Bailey, P. A., Hitzemann, K., Pittelkow, M. R., and Maihle, N. J., Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells. Mol. Biol. Cell. 5, 339-347 (1994). 

Y4. Yeh, S., Miyamoto, H., Nishimura, K., Kang, H., Ludlow, J., et al., Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem. Biophys. Res. Commun. 248, 361-367 (1998). 

Z4. Zhu, X., and Liu, J. R, Steroid-independent activation of androgen receptor in androgen-independent prostate cancer A possible role for the MAP kinase signal transduction pathway Mol. Cell. Endocrinol. 134, 9-14 (1997). 

---